Beeline Medicines launched with a $300 million Series A led by Bain Capital to pursue a portfolio of five in-licensed programs from Bristol Myers Squibb targeting immune-mediated diseases. The funding is intended to support dedicated development execution across the suite, with lupus positioned as the lead therapeutic area. At the center of the pipeline is afimetoran, a once-daily oral selective TLR7/8 inhibitor for systemic lupus erythematosus, already backed by clinical proof-of-concept in cutaneous lupus erythematosus and granted fast track designation for systemic lupus erythematosus in May 2025. Beeline expects a Phase II trial (NCT04895696) to complete in the second half of 2026. The broader lineup includes BMS-986326 (an IL-2–CD25 fusion protein intended to enhance regulatory T cells), lomedeucitinib (a TYK2 inhibitor for rare immune diseases), and additional biologic targets aimed at IL-18 and IL-10 pathways. For biotech dealmaking watchers, the creation of an independent company from late-stage assets underscores how sponsors are extracting value by carving out portfolios—particularly when acquisition terms or development timelines benefit from a focused leadership and funding structure.